Robyn K. Pollom

403 total citations
18 papers, 290 citations indexed

About

Robyn K. Pollom is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Genetics. According to data from OpenAlex, Robyn K. Pollom has authored 18 papers receiving a total of 290 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Surgery and 5 papers in Genetics. Recurrent topics in Robyn K. Pollom's work include Diabetes Management and Research (15 papers), Diabetes Treatment and Management (11 papers) and Pancreatic function and diabetes (8 papers). Robyn K. Pollom is often cited by papers focused on Diabetes Management and Research (15 papers), Diabetes Treatment and Management (11 papers) and Pancreatic function and diabetes (8 papers). Robyn K. Pollom collaborates with scholars based in United States, Germany and Canada. Robyn K. Pollom's co-authors include Liza L. Ilag, Melvin Prince, William J. Huster, Julio Rosenstock, Priscilla Hollander, Dominik Dahl, Thomas Blevins, Anuj Bhargava, Irene Hadjiyianni and Mark A. Deeg and has published in prestigious journals such as Diabetes, Diabetes Obesity and Metabolism and International Journal of Clinical Practice.

In The Last Decade

Robyn K. Pollom

18 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robyn K. Pollom United States 8 222 87 86 78 64 18 290
Irene Nowotny Germany 7 170 0.8× 116 1.3× 54 0.6× 36 0.5× 24 0.4× 11 211
Ioanna Kosteria Greece 9 77 0.3× 48 0.6× 80 0.9× 59 0.8× 7 0.1× 19 225
Imran Pirwany Canada 7 79 0.4× 21 0.2× 11 0.1× 49 0.6× 18 0.3× 10 390
Saud Alsifri Saudi Arabia 9 336 1.5× 122 1.4× 137 1.6× 13 0.2× 2 0.0× 26 398
Randi Grøn Denmark 8 217 1.0× 52 0.6× 23 0.3× 25 0.3× 3 0.0× 14 302
Anna Parkkola Finland 10 168 0.8× 137 1.6× 202 2.3× 7 0.1× 21 0.3× 11 252
Lorella Battini Italy 13 46 0.2× 80 0.9× 11 0.1× 102 1.3× 38 0.6× 28 365
Jun‐Woo Ahn South Korea 11 122 0.5× 24 0.3× 10 0.1× 84 1.1× 34 0.5× 22 315
Francesca Sagnella Italy 12 78 0.4× 10 0.1× 20 0.2× 43 0.6× 50 0.8× 18 366
F. Storms United Kingdom 8 398 1.8× 99 1.1× 99 1.2× 4 0.1× 3 0.0× 12 441

Countries citing papers authored by Robyn K. Pollom

Since Specialization
Citations

This map shows the geographic impact of Robyn K. Pollom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robyn K. Pollom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robyn K. Pollom more than expected).

Fields of papers citing papers by Robyn K. Pollom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robyn K. Pollom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robyn K. Pollom. The network helps show where Robyn K. Pollom may publish in the future.

Co-authorship network of co-authors of Robyn K. Pollom

This figure shows the co-authorship network connecting the top 25 collaborators of Robyn K. Pollom. A scholar is included among the top collaborators of Robyn K. Pollom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robyn K. Pollom. Robyn K. Pollom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Aronson, Ronnie, Torben Biester, Jennifer Leohr, et al.. (2023). Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obesity and Metabolism. 25(7). 1964–1972. 3 indexed citations
2.
Wadwa, R. Paul, et al.. (2022). Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial. Diabetes Obesity and Metabolism. 25(1). 89–97. 12 indexed citations
3.
Aronson, Ronnie, Helle Linnebjerg, Jennifer Leohr, et al.. (2020). 1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D). Diabetes. 69(Supplement_1). 1 indexed citations
4.
5.
6.
Perez‐Nieves, Magaly, et al.. (2018). Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2. Generics and Biosimilars Initiative Journal. 7(2). 56–62. 2 indexed citations
7.
Ilag, Liza L., Timothy M. Costigan, Mark A. Deeg, et al.. (2017). Clinical Outcomes of Patients with Diabetes Who Exhibit Upper-Quartile Insulin Antibody Responses After Treatment with LY2963016 or Lantus® Insulin Glargine. Diabetes Therapy. 8(3). 545–554. 7 indexed citations
8.
Polonsky, William H., Lawrence Fisher, Pamela Kushner, et al.. (2017). Initiating insulin: How to help people with type 2 diabetes start and continue insulin successfully. International Journal of Clinical Practice. 71(8). e12973–e12973. 28 indexed citations
9.
Pollom, Robyn K., et al.. (2017). Biosimilar insulins: What do you need to know?. 14(1). 32–35. 4 indexed citations
10.
Pollom, Robyn K., et al.. (2016). Similar Efficacy and Safety of LY2963016 Insulin Glargine and Insulin Glargine (Lantus®) in Patients with T2D in Age Groups (<65, ≥65 Years). Canadian Journal of Diabetes. 40(5). S40–S40. 1 indexed citations
11.
Hadjiyianni, Irene, et al.. (2016). Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine. Diabetes Obesity and Metabolism. 18(4). 425–429. 23 indexed citations
12.
Blevins, Thomas, Dominik Dahl, Julio Rosenstock, et al.. (2015). Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( L antus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obesity and Metabolism. 17(8). 726–733. 61 indexed citations
13.
14.
Ilag, Liza L., Mark A. Deeg, Timothy M. Costigan, et al.. (2015). Evaluation of immunogenicity of LY2963016 insulin glargine compared with L antus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 18(2). 159–168. 32 indexed citations
15.
Deeg, Mark A., Liza L. Ilag, William J. Huster, et al.. (2014). Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM or T2DM. Canadian Journal of Diabetes. 38(5). S52–S53. 1 indexed citations
16.
Blevins, Thomas, Dominik Dahl, Julio Rosenstock, et al.. (2014). Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study. Canadian Journal of Diabetes. 38(5). S53–S53. 2 indexed citations
17.
Pollom, Robyn K., et al.. (2007). Clinical analytics equal better systemwide outcomes. Nursing Management. 38(12). 44–44. 1 indexed citations
18.
Pollom, Robyn K., et al.. (2004). Utilization of a Multidisciplinary Team for Inpatient Diabetes Care. Critical Care Nursing Quarterly. 27(2). 185–188. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Irene Nowotny Breakdown of academic impact, for papers by Ioanna Kosteria Breakdown of academic impact, for papers by Imran Pirwany Breakdown of academic impact, for papers by Saud Alsifri Breakdown of academic impact, for papers by Randi Grøn Breakdown of academic impact, for papers by Anna Parkkola Breakdown of academic impact, for papers by Lorella Battini Breakdown of academic impact, for papers by Jun‐Woo Ahn Breakdown of academic impact, for papers by Francesca Sagnella Breakdown of academic impact, for papers by F. Storms
Rankless by CCL
2026